Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides

Biomaterials

Volumn 34, Issue 32, 2013, Pages 7939-7949

  Ming, Xin ^a   Carver, Kyle ^a   Wu, Lin ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Albumin; Conjugation; Targeted delivery; Therapeutic oligonucleotides

Indexed keywords

ALBUMIN; ANTISENSE OLIGONUCLEOTIDES; CONJUGATION; FUNCTIONAL ACTIVITIES; HUMAN SERUM ALBUMINS; NANOMOLAR CONCENTRATION; TARGETED DELIVERY; TARGETING LIGANDS;

CYTOTOXICITY; MOLECULES; NANOCONJUGATES; NANOPARTICLES; TUMORS;

OLIGONUCLEOTIDES;

ALBUMIN; MORPHOLINO OLIGONUCLEOTIDE; NANOCONJUGATE;

ARTICLE; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; DRUG TARGETING; PARTICLE SIZE; PRIORITY JOURNAL; SPHEROID CELL; TUMOR CELL;

EID: 84881024344     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.066     Document Type: Article

References (39)

1. Juliano R., Alam M.R., Dixit V., Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008, 36:4158-4171.
2. Kole R., Krainer A.R., Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012, 11:125-140.
3. Bauman J.A., Kole R. Modulation of RNA splicing as a potential treatment for cancer. Bioeng Bugs 2011, 2:125-128.
4. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9:775-789.
5. Bauman J.A., Li S.D., Yang A., Huang L., Kole R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res 2010, 38:8348-8356.
6. Zammarchi F., de Stanchina E., Bournazou E., Supakorndej T., Martires K., Riedel E., et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A 2011, 108:17779-17784.
7. Ming X. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin Drug Deliv 2011, 8:435-449.
8. Juliano R. Nanomedicine: is the wave cresting?. Nat Rev Drug Discov 2013, 12:171-172.
9. Huang L., Sullenger B., Juliano R. The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides. JDrug Target 2010, 18:567-574.
10. Juliano R., Bauman J., Kang H., Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 2009, 6:686-695.
11. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
12. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
13. Kwon I.K., Lee S.C., Han B., Park K. Analysis on the current status of targeted drug delivery to tumors. JControl Release 2012, 164:108-114.
14. Ruenraroengsak P., Cook J.M., Florence A.T. Nanosystem drug targeting: facing up to complex realities. JControl Release 2010, 141:265-276.
15. Chauhan V.P., Stylianopoulos T., Boucher Y., Jain R.K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011, 2:281-298.
16. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
17. Juliano R.L., Carver K., Cao C., Ming X. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. JDrug Target 2013, 21:27-43.
18. Muro S. Challenges in design and characterization of ligand-targeted drug delivery systems. JControl Release 2012, 164:125-137.
19. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
20. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. JControl Release 2006, 114:100-109.
21. Juliano R.L., Ming X., Nakagawa O., Xu R., Yoo H. Integrin targeted delivery of gene therapeutics. Theranostics 2011, 1:211-219.
22. Abes R., Arzumanov A.A., Saleh A.F., Said Hassane F., Gait M.J., Lebleu B. Splice redirection as a convenient assay to monitor CPP-ON efficiency and mechanism. Methods Mol Biol 2011, 683:307-320.
23. Alam M.R., Dixit V., Kang H., Li Z.B., Chen X., Trejo J., et al. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res 2008, 36:2764-2776.
24. Felding-Habermann B., Mueller B.M., Romerdahl C.A., Cheresh D.A. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. JClin Invest 1992, 89:2018-2022.
25. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L.A. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009, 4:309-324.
26. Deneke S.M. Thiol-based antioxidants. Curr Top Cell Regul 2000, 36:151-180.
27. Ming X., Carver K., Fisher M., Noel R., Cintrat J.C., Gillet D., et al. The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res 2013, 41:3673-3687.
28. Ming X., Sato K., Juliano R.L. Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. JControl Release 2011, 153:83-92.
29. Ming X., Feng L. Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate. Mol Pharm 2012, 9:1502-1510.
30. Dohmen C., Edinger D., Frohlich T., Schreiner L., Lachelt U., Troiber C., et al. Nanosized multifunctional polyplexes for receptor-mediated siRNA delivery. ACS Nano 2012, 6:5198-5208.
31. Juliano R.L., Ming X., Nakagawa O. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem 2012, 23:147-157.
32. Montet X., Funovics M., Montet-Abou K., Weissleder R., Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. JMed Chem 2006, 49:6087-6093.
33. Cirak S., Arechavala-Gomeza V., Guglieri M., Feng L., Torelli S., Anthony K., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011, 378:595-605.
34. Sazani P., Kang S.H., Maier M.A., Wei C., Dillman J., Summerton J., et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res 2001, 29:3965-3974.
35. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.
36. Mehta G., Hsiao A.Y., Ingram M., Luker G.D., Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. JControl Release 2012, 164:192-204.
37. Huang K., Ma H., Liu J., Huo S., Kumar A., Wei T., et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors invivo. ACS Nano 2012, 6:4483-4493.
38. Goodman T.T., Olive P.L., Pun S.H. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int J Nanomedicine 2007, 2:265-274.
39. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. JControl Release 2008, 132:171-183.